Infection Viral, Myocarditis Allergic, Renal Dialysis, Severe Acute Respiratory Syndrome-related Coronavirus, Vaccines
Conditions
Keywords
immune infection, neural infection, spike 2 protein, poison, SARS-CoV-2, precarditis
Brief summary
The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.
Interventions
DRUGNifedipine 30 MG
Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
DIAGNOSTIC_TESTKangzhu BPCB0A-3A
The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
BEHAVIORALLow Mobility
The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
DRUGEnalapril Maleate 10Mg Tab
The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
DRUGLansoprazole 30Mg Ec Cap
The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
DRUGMetoprolol Succinate
Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
DIETARY_SUPPLEMENTCoenzyme Q10
200 mg per day is used for supplement with the cardiac interventions.
DIETARY_SUPPLEMENTd-alpha tocopherol acetate
The 268 mg twice per day dietary healthcare is the patient's usual daily use.
DIETARY_SUPPLEMENTOmega-3
The 900 mg twice per day dietary healthcare is the patient's usual daily use.
DRUGDuloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release
Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
DRUGSuperoxide Dismutase
Superoxide Dismutase is used to substitute the missing of antiviral drugs.
Sponsors
Yang I. Pachankis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The crossover model intervenes on the precarditis and myocarditis happenings on the patient, and evaluates the cause of the symptoms. Basic medicines are tested against the pathogens with the immune responses of the patient.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.
Exclusion criteria
* healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series * persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet Distribution | 10 days | Platelet distribution is measured to determine the viral induced blood-borne pathogen in the physiological responses of the patient. |
| Heart Rate | 1 day | The heart rate is monitored daily, and the primary goal is to stabilize the patient's heart rate. |
| Electrocardiogram | 20 days | Electrocardiogram reflects the blood pressure management on the patient's health outcome and potential risks. |
| Basophil Absolute Number | 10 days | Basophil Absolute Number is measured on the counteraction of the patient's immune system integrities against the rapid acidification of the viral infection. |
| Mean Platelet Volume | 10 days | MPV is measured to determine the risks in blood clot and internal vein scratches in the patient. |
| Eosinophil Absolute Number | 10 days | Eosinophil Absolute Number is measured to determine the intensities of infection in the patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac Enzymes | 10 days | Cardiac enzymes are measured to locate and eliminate the symptoms' causes, identify potential health risks, and to determine if subsidiary treatments are needed. |
Countries
China
Outcome results
None listed